> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Senseonics Glucose Monitor
- URL: https://www.fdaweb.com/regulatory-review-period-for-senseonics-glucose-monitor/
- Published: 2020-09-10T12:00:00.000Z
- Updated: 2026-09-14T16:28:25.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147620

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Senseonics’ Eversense Continuous Glucose Monitoring System, indicated for continually measuring glucose levels in adults with diabetes for up to 90 days. The regulatory review period is 3,727 days, which includes 3,123 days that occurred during the testing phase and 604 days during the approval phase. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-20040.pdf?ref=fdaweb.com).